OriGene Technologies Raises $21.3 Million in Series C Funding
Published: Mar 22, 2013
About OriGene Technologies
OriGene Technologies, Inc. develops, manufactures, and sells genome wide research and diagnostic products worldwide. OriGene has developed an extensive array of ultra-specific monoclonal antibodies called UltraMAB which offers significant improvement over traditional antibodies. UltraMAB antibodies are validated by OriGene's proprietary high density microarray technology for a wide variety of antibody applications.
For more information, visit www.origene.com.
SOURCE OriGene Technologies, Inc.